Abstract Number: 346 • 2013 ACR/ARHP Annual Meeting
Rheumatoid Arthritis, a More Severe Disease Than Psoriatic Arthritis? A Comparison Of Disease Activity In Patients With Psoriatic Arthritis and Rheumatoid Arthritis From The Swedish Early Psoriatic Arthritis Registry (SwePsA) and The Swedish Rheumatology Registry For Early RA (SRR)
Background/Purpose: In clinical practise patients with psoriatic arthritis (PsA) seem to have milder disease expression compared with patients having rheumatoid arthritis (RA). Studies have, however,…Abstract Number: 347 • 2013 ACR/ARHP Annual Meeting
Factors Explaining The Discrepancy Between Patient and Physician Global Assessment Of Disease Activity In Psoriatic Arthritis
Background/Purpose: Patients and physicians often perceive the extent of disease activity differently. We aimed to assess the factors contributing to the variability in scoring of…Abstract Number: 348 • 2013 ACR/ARHP Annual Meeting
Laboratory Abnormalities In Patients With Psoriatic Arthritis Receiving Apremilast, An Oral Phosphodiesterase 4 Inhibitor: Pooled Safety Analysis Of Three Phase 3, Randomized, Controlled Trials
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate inflammatory mediators. The PALACE 1, 2, and 3 trials compared the efficacy and…Abstract Number: 349 • 2013 ACR/ARHP Annual Meeting
Serum CTX-I Predicts Systemic Bone Loss At The Hip Over 1 Year In Patients With Early Psoriatic Arthritis
Background/Purpose: There is a growing interest in bone and cartilage biomarkers that could be used predicting and assessing changes in structural damage in inflammatory arthritis.…Abstract Number: 350 • 2013 ACR/ARHP Annual Meeting
Cortical Bone Density As Measured By Digital X-Ray Radiogrammetry Correlates with Radiographic Joint Damage In The Hands Within 1 Year In Psoriatic Arthritis
Background/Purpose: Structural destruction in peripheral joints may occur over time in both PsA and RA. We previously reported that 47% of early PsA patients treated…Abstract Number: 351 • 2013 ACR/ARHP Annual Meeting
Psoriatic Arthritis Mutilans: Clinical and Radiographic Definitions. A Systematic Review
Background/Purpose: Psoriatic Arthritis Mutilans (PAM) is the most severe form of psoriatic arthritis. Research on PAM has been impeded by the lack of an accepted…Abstract Number: 352 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Vaccination Against seasonal 2012 Influenza Virus Among Patients With Psoriatic Arthritis and Psoriasis
Background/Purpose: Patients with psoriatic arthritis (PsA) and psoriasis (Pso) are considered to be immunosuppressed and are therefore recommended to receive vaccination against seasonal influenza. However,…Abstract Number: 353 • 2013 ACR/ARHP Annual Meeting
Time Interval Between The Onset Of Psoriasis and The Onset Of Psoriatic Arthritis May Define Disease Subsets
Background/Purpose: Psoriatic Arthritis (PsA) is a heterogeneous disease with widely varying clinical features and outcomes. Phenotypic heterogeneity may reflect genetic heterogeneity. We aimed to investigate…Abstract Number: 354 • 2013 ACR/ARHP Annual Meeting
Disease Burden Among Patients With Psoriatic Arthritis Who Have Experienced First Line Tumor Necrosis Factor Inhibitor Regimen Failure In The European Union
Background/Purpose: Data on second line biologic patients who have experienced 1st line tumor necrosis factor inhibitor (TNF) failure and associated disease burden among patients (pts)…Abstract Number: 355 • 2013 ACR/ARHP Annual Meeting
Response To Etanercept With Or Without Methotrexate Combination Therapy In Patients With Psoriatic Arthritis
Background/Purpose: Randomized controlled trials in psoriatic arthrtitis (PsA) have allowed treatment with TNF inhibitors (TNFi) as monotherapy as well as co-medication with methotrexate (MTX), but…Abstract Number: 356 • 2013 ACR/ARHP Annual Meeting
Outcomes Of Patients With Rheumatoid Arthritis and Comorbid Hyperlipidemia
Background/Purpose: Patients (pts) with RA have an increased prevalence of cardiovascular disease (CVD). Whether due to comorbidity or related to RA medications, many pts with…Abstract Number: 358 • 2013 ACR/ARHP Annual Meeting
Inflammatory Burden Predicts Carotid Plaque Progression and Subsequent Cardiovascular Events In Rheumatoid Arthritis: The 2-Year Prospective Cohort Study
Background/Purpose: Rheumatoid arthritis (RA) patients have increased prevalence of carotid atherosclerosis, especially plaque formation, which has been associated with inflammatory burden in a previous study.…Abstract Number: 359 • 2013 ACR/ARHP Annual Meeting
Tocilizumab Treatment Increases Left Ventricular Ejection Fraction and Decreases Left Ventricular Mass Index In Rheumatoid Arthritis Patients Without Cardiac Symptoms : Assessment By Cardiac Magnetic Resonance Imaging At 3.0 Tesla
Background/Purpose: Left ventricular (LV) dysfunction in rheumatoid arthritis (RA) may result, at least in part, from inflammation that may be regional and global. Therefore, therapies…Abstract Number: 320 • 2013 ACR/ARHP Annual Meeting
Sustained Improvement In Health-Related Quality Of Life, Work Productivity, Employability, and Reduced Healthcare Resource Utilization Of Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Treated With Golimumab: 5-Year Results From 3 Phase III Studies
Background/Purpose: To summarize changes from baseline in health-related quality of life (HRQOL), impact of disease on work productivity, employability, and healthcare resource utilization among patients…Abstract Number: 321 • 2013 ACR/ARHP Annual Meeting
Evaluation and Comparison Of Performance Of Different Classification Criteria For Reactive Arthritis
Background/Purpose: Reactive Arthritis (Re.A) is an inflammatory joint disease that according to different records represents from 6% to 47% of the seronegative spondyloarthropathies (SS). These…
ACR Meeting Abstracts